sexta-feira, 21 de agosto de 2026
PesquisarExplore
pt.VIA.NEWS
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,977
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,977 factos verificados com a fonte5,242 documentos-fonte arquivados
Trabalhe com estes dados → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· November 27, 2025

CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi

View original at globenewswire.com
CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi Dublin, Nov…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • CD38 is an attractive target for antibody therapy because it is highly expressed on malignant plasma cells

    100% confidence

  • CD38 is a clinically validated and commercially very successful target

    100% confidence

  • Multiple Myeloma represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors

    100% confidence

  • The patent holder of Darzalex expects that royalties from sales of DARZALEX will begin to decline materially in 2029 following expiration of U.S. patent rights on daratumumab

    95% confidence

Citado nestas reportagens da Via News